Niagen Biosciences: The Rise of an NAD+ Pioneer in the Health Market
Reading Time: 3 minutes
Niagen is a leading company in the growing NAD+ supplement market, benefiting from its flagship product Tru Niagen, which aligns with increasing health and longevity trends as well as strong brand recognition. Recent FDA approvals as "Orphan Drug" and "Rare Pediatric Disease," along with positive study results for rare diseases such as Werner syndrome, open up new lucrative pharmaceutical markets for Niagen Biosciences. Niagen Biosciences backs its products with extensive clinical validation and a strong IP portfolio of over 50 patents....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
